MX369315B - Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. - Google Patents
Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos.Info
- Publication number
- MX369315B MX369315B MX2016004455A MX2016004455A MX369315B MX 369315 B MX369315 B MX 369315B MX 2016004455 A MX2016004455 A MX 2016004455A MX 2016004455 A MX2016004455 A MX 2016004455A MX 369315 B MX369315 B MX 369315B
- Authority
- MX
- Mexico
- Prior art keywords
- levodopa
- controlled release
- muco
- adhesive
- esters
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La invención proporciona una formulación oral sólida de liberación controlada que comprende (a) un componente de liberación controlada que comprende un núcleo que comprende levodopa y/o un éster de levodopa o sus sales, en donde el núcleo está recubierto con una capa de un polímero muco-adhesivo y recubierto externamente con una capa de un polímero de recubrimiento entérico; y (b) un componente inhibidor de descarboxilasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361887762P | 2013-10-07 | 2013-10-07 | |
PCT/US2014/059554 WO2015054302A1 (en) | 2013-10-07 | 2014-10-07 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016004455A MX2016004455A (es) | 2016-06-21 |
MX369315B true MX369315B (es) | 2019-11-05 |
Family
ID=52813592
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004455A MX369315B (es) | 2013-10-07 | 2014-10-07 | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
MX2019013171A MX2019013171A (es) | 2013-10-07 | 2016-04-07 | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019013171A MX2019013171A (es) | 2013-10-07 | 2016-04-07 | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
Country Status (12)
Country | Link |
---|---|
US (4) | US10098845B2 (es) |
EP (2) | EP3782614A1 (es) |
JP (3) | JP6506271B2 (es) |
KR (2) | KR102266091B1 (es) |
CN (1) | CN105658211A (es) |
AU (3) | AU2014332024B2 (es) |
CA (1) | CA2926082C (es) |
ES (1) | ES2823000T3 (es) |
IL (2) | IL244920B (es) |
MX (2) | MX369315B (es) |
PL (1) | PL3054929T3 (es) |
WO (1) | WO2015054302A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2234963B1 (en) | 2007-12-28 | 2020-04-08 | Impax Laboratories, LLC | Controlled release formulations of levodopa and uses thereof |
MX369315B (es) | 2013-10-07 | 2019-11-05 | Impax Laboratories Inc | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
US10987313B2 (en) * | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
WO2016046817A1 (en) * | 2014-09-24 | 2016-03-31 | Vital Beverages Global Inc. | Compositions and methods for selective gi tract delivery |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US11759417B2 (en) * | 2018-02-28 | 2023-09-19 | Shanghai Wd Pharmaceutical Co., Ltd | Pharmaceutical composition and preparation method therefor and use thereof |
US11911513B2 (en) | 2018-05-23 | 2024-02-27 | Shanghai Wd Pharmaceutical Co., Ltd | Controlled-release system of active pharmaceutical ingredient and preparation method therefor |
WO2019223753A1 (zh) * | 2018-05-23 | 2019-11-28 | 上海汉都医药科技有限公司 | 活性药物成分的控释系统及其制备方法 |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
CN110075345B (zh) * | 2019-04-01 | 2021-12-10 | 杭州英健生物科技有限公司 | 适用于胃窥镜喷涂到胃损伤黏膜表面的双组分自粘性胃黏膜保护胶及其应用 |
WO2022140448A1 (en) * | 2020-12-22 | 2022-06-30 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
CN114762684B (zh) * | 2021-01-14 | 2023-11-21 | 华益泰康药业股份有限公司 | 一种治疗帕金森的缓释胶囊及其制备方法 |
WO2024024865A1 (ja) * | 2022-07-28 | 2024-02-01 | 大原薬品工業株式会社 | レボドパ持続性製剤 |
US11931224B1 (en) * | 2022-12-19 | 2024-03-19 | Robert Parker | Tooth pod |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3891696A (en) | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
DE2513940A1 (de) | 1975-03-29 | 1976-10-14 | Merck Patent Gmbh | Pharmazeutische zubereitung |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
DE3126703A1 (de) | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
US5188840A (en) | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
DE3779500T2 (de) | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
ZA889189B (en) | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
NZ220599A (en) | 1986-06-16 | 1990-10-26 | Merck & Co Inc | Controlled release oral dosage formulation of carbidopa and levodopa |
US5283352A (en) | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
FI864875A0 (fi) | 1986-11-28 | 1986-11-28 | Orion Yhtymae Oy | Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa. |
YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
EP0313845A1 (en) | 1987-09-29 | 1989-05-03 | Warner-Lambert Company | Stabilization of enteric coated dosage form |
US4938968A (en) | 1988-07-26 | 1990-07-03 | Norjec Development Associates, Inc. | Controlled release indomethacin |
IT1229856B (it) | 1989-04-20 | 1991-09-13 | Recordati Chem Pharm | Compresse a rilascio controllato contenenti flavossato. |
GB2238047B (en) | 1989-11-03 | 1993-02-10 | Orion Yhtymae Oy | Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation |
IE66933B1 (en) | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
US5624960A (en) | 1991-01-23 | 1997-04-29 | Isis Pharma Gmbh | Orally administrable drugs for the treatment of central dopamine deficiency conditions |
DE4101873C2 (de) | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
US5388857A (en) | 1992-08-27 | 1995-02-14 | Badger Equipment Company | Operator controlled vehicle stabilizer |
IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
GB9309749D0 (en) | 1993-05-12 | 1993-06-23 | Boots Co Plc | Therapeutic agents |
IT1264517B1 (it) | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
IT1266565B1 (it) | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
WO1995003052A1 (en) | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
US6183778B1 (en) | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
US5840756A (en) | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
IT1282576B1 (it) | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
IT1289160B1 (it) | 1997-01-08 | 1998-09-29 | Jagotec Ag | Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di |
US6756056B2 (en) | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
IT1293764B1 (it) | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
IT1295271B1 (it) | 1997-10-03 | 1999-05-04 | Chiesi Farma Spa | Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato |
US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
US5945424A (en) | 1998-07-31 | 1999-08-31 | G & H Associates, Inc. | Treatment of periodic limb movement syndrome |
WO2000015197A1 (en) | 1998-09-14 | 2000-03-23 | Rubin Alan A | Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
NZ511442A (en) | 1998-11-02 | 2003-02-28 | Elan Corp Plc | Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl |
WO2000027385A1 (en) | 1998-11-10 | 2000-05-18 | Teva Pharmaceutical Industries, Ltd., Et Al. | Dispersible compositions containing l-dopa ethyl ester |
EP1140012B1 (en) | 1998-12-17 | 2004-03-03 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
PT1227806E (pt) | 1999-11-11 | 2005-10-31 | Pfizer Health Ab | Formulacao farmaceutica contendo tolterodina e sua utilizacao |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
EP1305021A4 (en) | 2000-06-23 | 2009-09-23 | Teva Pharma | RAPID EXPANSION COMPOSITION FOR GASTRIC RETENTION AND REGULATED RELEASE OF THERAPEUTIC AGENTS, AND DOSAGE FORMS COMPRISING THE SAME |
US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
US6531153B2 (en) | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
IL159813A0 (en) | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core |
IL159812A0 (en) * | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US20040166159A1 (en) | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
US20030224045A1 (en) | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
WO2004062577A2 (en) | 2003-01-03 | 2004-07-29 | Shire Laboratories Inc. | Two or more enteric materials to regulate drug release |
ES2665464T3 (es) | 2003-03-28 | 2018-04-25 | Sigmoid Pharma Limited | Forma de dosificación oral sólida que contiene microcápsulas sin costuras |
WO2004109927A1 (en) * | 2003-06-04 | 2004-12-16 | Koninklijke Philips Electronics N.V. | Bit-detection arrangement and apparatus for reproducing information |
US20050070608A1 (en) | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
US8007827B2 (en) | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
US8015148B2 (en) | 2004-06-30 | 2011-09-06 | International Business Machines Corporation | Selective profiler for use with transaction processing applications |
JP2006018748A (ja) * | 2004-07-05 | 2006-01-19 | Canon Inc | 情報処理装置及びその制御方法、並びにコンピュータプログラム及びコンピュータ可読記憶媒体 |
JP2008516893A (ja) | 2004-08-27 | 2008-05-22 | スフェリックス,インク. | 多層錠剤および生体接着性剤形 |
US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
WO2006133349A2 (en) * | 2005-06-08 | 2006-12-14 | Alpharma, Inc. | Orally disintegrable sleep aid formulations |
US20070003621A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
WO2007002518A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
US20070275060A1 (en) | 2005-08-05 | 2007-11-29 | Osmotica Costa Rica Sociedad Anonima | Extended release solid pharmaceutical composition containing carbidopa and levodopa |
RU2442574C2 (ru) | 2005-08-22 | 2012-02-20 | Новартис Аг | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ |
FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
ES2550035T3 (es) | 2006-01-27 | 2015-11-04 | Adare Pharmaceuticals, Inc. | Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos |
CN101410093A (zh) | 2006-01-27 | 2009-04-15 | 欧兰德股份有限公司 | 包含弱碱性药物和有机酸的药物递送系统 |
US8637080B2 (en) * | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
EP2234963B1 (en) | 2007-12-28 | 2020-04-08 | Impax Laboratories, LLC | Controlled release formulations of levodopa and uses thereof |
KR20130088890A (ko) | 2008-04-24 | 2013-08-08 | 인다이스 피티와이 엘티디 | 전력제어 |
US20100331244A1 (en) | 2009-06-01 | 2010-12-30 | The University Of Tokyo | Pharmaceutical composition, food or drink, and methods related thereto |
ES2565644T3 (es) * | 2009-11-09 | 2016-04-06 | Xenoport, Inc. | Composiciones farmacéuticas y formas de dosificación oral de un pre medicamento de levodopa y los métodos de utilización |
WO2012136819A1 (en) | 2011-04-05 | 2012-10-11 | Athera Biotechnologies Ab | Therapeutic and prophylactic methods, uses and compositions comprising anexin a5 |
EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
US20130195973A1 (en) | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
MX369315B (es) * | 2013-10-07 | 2019-11-05 | Impax Laboratories Inc | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
-
2014
- 2014-10-07 MX MX2016004455A patent/MX369315B/es active IP Right Grant
- 2014-10-07 PL PL14851749T patent/PL3054929T3/pl unknown
- 2014-10-07 AU AU2014332024A patent/AU2014332024B2/en active Active
- 2014-10-07 EP EP20186769.4A patent/EP3782614A1/en active Pending
- 2014-10-07 KR KR1020167011939A patent/KR102266091B1/ko active IP Right Grant
- 2014-10-07 CA CA2926082A patent/CA2926082C/en active Active
- 2014-10-07 WO PCT/US2014/059554 patent/WO2015054302A1/en active Application Filing
- 2014-10-07 KR KR1020217017860A patent/KR102356190B1/ko active IP Right Grant
- 2014-10-07 US US15/027,654 patent/US10098845B2/en active Active
- 2014-10-07 JP JP2016521328A patent/JP6506271B2/ja active Active
- 2014-10-07 CN CN201480055451.3A patent/CN105658211A/zh active Pending
- 2014-10-07 ES ES14851749T patent/ES2823000T3/es active Active
- 2014-10-07 EP EP14851749.3A patent/EP3054929B1/en active Active
-
2016
- 2016-04-05 IL IL244920A patent/IL244920B/en active IP Right Grant
- 2016-04-06 US US15/092,086 patent/US10292935B2/en active Active
- 2016-04-07 MX MX2019013171A patent/MX2019013171A/es unknown
-
2019
- 2019-03-21 US US16/360,936 patent/US10688058B2/en active Active
- 2019-03-27 JP JP2019059915A patent/JP6898375B2/ja active Active
- 2019-12-23 AU AU2019284060A patent/AU2019284060B2/en active Active
-
2020
- 2020-02-19 IL IL272772A patent/IL272772B/en unknown
- 2020-05-01 US US16/864,323 patent/US10973769B2/en active Active
-
2021
- 2021-06-09 JP JP2021096298A patent/JP2021127349A/ja active Pending
- 2021-12-06 AU AU2021282393A patent/AU2021282393B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013171A (es) | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. | |
IL257521A (en) | Compositions comprising a pi3k inhibitor and an hdac inhibitor | |
TWI561593B (en) | Anti-corrosive coating composition, anti-corrosive coating film and anti-corrosive method of base member | |
EP3188725A4 (en) | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof | |
EP3572400A4 (en) | EZH2 INHIBITOR AND USE OF IT | |
EP3773580A4 (en) | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND THEIR USES | |
PH12016501034A1 (en) | Oral care compositions and methods | |
IL223865B (en) | Calcium salts of dihydroortate dehydrogenase inhibitors, preparations containing them and their uses | |
EP3426243A4 (en) | INHIBITORS OF 3-PHOSPHOGLYCERERA DEHYDROGENASE AND USES THEREOF | |
EP3426244A4 (en) | INHIBITORS OF 3-PHOSPHOGLYCERERA DEHYDROGENASE AND USES THEREOF | |
PH12015502154A1 (en) | Composition for oral cavity | |
EP3660023A4 (en) | COMPOUND USED AS ACC INHIBITOR AND ASSOCIATED USE | |
MX2016008233A (es) | Composiciones para cuidado oral y metodos. | |
EP3643308A4 (en) | COUMARIN TYPE COMPOUND AS MEK INHIBITOR AND USES THEREOF | |
MX358871B (es) | Composiciones y metodos para el cuidado oral. | |
EP3730477A4 (en) | SULPHONIC ACID ESTER COMPOUND AND ASSOCIATED USE | |
MX354226B (es) | Composiciones para cuidado oral y métodos. | |
GEP201706743B (en) | Oral formulation for the treatment of cardiovascular diseases | |
MX2021001790A (es) | Composiciones solidas de trigliceridos y usos de estas. | |
CL2016000179A1 (es) | Formulación de combinación que contiene metformina de liberación prolongada e inhibidor de la hmg-coa reductasa de liberación inmediata. | |
MX354872B (es) | Composiciones para cuidado oral y metodos. | |
MX362315B (es) | Imidazolcarboxamidas y su uso como inhibidores de amida de acidos grasos hidrolasa (faah). | |
MX2017003878A (es) | Formulacion farmaceutica para reducir contracciones de la vejiga y metodo para utilizar la misma. | |
EP3377476A4 (en) | HYDROGEN ISOTOPE ENRICHED ANALOGS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF | |
MX356027B (es) | Composiciones para cuidado oral y metodos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |